These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 26178773)
1. Genetic test reporting enhances understanding of risk information and acceptance of prevention recommendations compared to family history-based counseling alone. Taber JM; Aspinwall LG; Stump TK; Kohlmann W; Champine M; Leachman SA J Behav Med; 2015 Oct; 38(5):740-53. PubMed ID: 26178773 [TBL] [Abstract][Full Text] [Related]
2. Genetic test reporting of CDKN2A provides informational and motivational benefits for managing melanoma risk. Aspinwall LG; Stump TK; Taber JM; Drummond DM; Kohlmann W; Champine M; Leachman SA Transl Behav Med; 2018 Jan; 8(1):29-43. PubMed ID: 29385581 [TBL] [Abstract][Full Text] [Related]
3. CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families. Aspinwall LG; Leaf SL; Dola ER; Kohlmann W; Leachman SA Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1510-9. PubMed ID: 18559569 [TBL] [Abstract][Full Text] [Related]
4. Priority of Risk (But Not Perceived Magnitude of Risk) Predicts Improved Sun-Protection Behavior Following Genetic Counseling for Familial Melanoma. Taber JM; Aspinwall LG; Drummond DM; Stump TK; Kohlmann W; Champine M; Cassidy P; Leachman SA Ann Behav Med; 2021 Feb; 55(1):24-40. PubMed ID: 32415830 [TBL] [Abstract][Full Text] [Related]
5. Impact of melanoma genetic test reporting on perceived control over melanoma prevention. Aspinwall LG; Stump TK; Taber JM; Kohlmann W; Leaf SL; Leachman SA J Behav Med; 2015 Oct; 38(5):754-65. PubMed ID: 25822116 [TBL] [Abstract][Full Text] [Related]
6. CDKN2A testing and genetic counseling promote reductions in objectively measured sun exposure one year later. Stump TK; Aspinwall LG; Drummond DM; Taber JM; Kohlmann W; Champine M; Cassidy PB; Petrie T; Liley B; Leachman SA Genet Med; 2020 Jan; 22(1):26-34. PubMed ID: 31371819 [TBL] [Abstract][Full Text] [Related]
7. Genetic testing for hereditary melanoma and pancreatic cancer: a longitudinal study of psychological outcome. Aspinwall LG; Taber JM; Leaf SL; Kohlmann W; Leachman SA Psychooncology; 2013 Feb; 22(2):276-89. PubMed ID: 23382133 [TBL] [Abstract][Full Text] [Related]
8. Genetic Test Reporting and Counseling for Melanoma Risk in Minors May Improve Sun Protection Without Inducing Distress. Stump TK; Aspinwall LG; Kohlmann W; Champine M; Hauglid J; Wu YP; Scott E; Cassidy P; Leachman SA J Genet Couns; 2018 Aug; 27(4):955-967. PubMed ID: 29349527 [TBL] [Abstract][Full Text] [Related]
9. Unaffected family members report improvements in daily routine sun protection 2 years following melanoma genetic testing. Aspinwall LG; Taber JM; Kohlmann W; Leaf SL; Leachman SA Genet Med; 2014 Nov; 16(11):846-53. PubMed ID: 24763292 [TBL] [Abstract][Full Text] [Related]
10. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling. Potrony M; Puig-Butillé JA; Aguilera P; Badenas C; Carrera C; Malvehy J; Puig S J Am Acad Dermatol; 2014 Nov; 71(5):888-95. PubMed ID: 25064638 [TBL] [Abstract][Full Text] [Related]
11. Melanoma genetic testing, counseling, and adherence to skin cancer prevention and detection behaviors. Glanz K; Volpicelli K; Kanetsky PA; Ming ME; Schuchter LM; Jepson C; Domchek SM; Armstrong K Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):607-14. PubMed ID: 23392000 [TBL] [Abstract][Full Text] [Related]
12. Parental preferences for CDKN2A/p16 testing of minors. Taber JM; Aspinwall LG; Kohlmann W; Dow R; Leachman SA Genet Med; 2010 Dec; 12(12):823-38. PubMed ID: 21045708 [TBL] [Abstract][Full Text] [Related]
13. Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway. Levin T; Mæhle L Fam Cancer; 2017 Apr; 16(2):257-265. PubMed ID: 27804060 [TBL] [Abstract][Full Text] [Related]
14. CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies. Helgadottir H; Höiom V; Tuominen R; Jönsson G; Månsson-Brahme E; Olsson H; Hansson J Int J Cancer; 2015 Nov; 137(9):2220-6. PubMed ID: 25943250 [TBL] [Abstract][Full Text] [Related]
15. Clinical applications of melanoma genetics. Gabree M; Patel D; Rodgers L Curr Treat Options Oncol; 2014 Jun; 15(2):336-50. PubMed ID: 24652319 [TBL] [Abstract][Full Text] [Related]
16. Role of Heredity in Melanoma Susceptibility: A Primer for the Practicing Surgeon. Abdo JF; Sharma A; Sharma R Surg Clin North Am; 2020 Feb; 100(1):13-28. PubMed ID: 31753108 [TBL] [Abstract][Full Text] [Related]
18. Genetic testing for melanoma risk: a prospective cohort study of uptake and outcomes among Australian families. Kasparian NA; Meiser B; Butow PN; Simpson JM; Mann GJ Genet Med; 2009 Apr; 11(4):265-78. PubMed ID: 19265718 [TBL] [Abstract][Full Text] [Related]
19. Pediatric melanoma in melanoma-prone families. Goldstein AM; Stidd KC; Yang XR; Fraser MC; Tucker MA Cancer; 2018 Sep; 124(18):3715-3723. PubMed ID: 30207590 [TBL] [Abstract][Full Text] [Related]